Skip to main navigation

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

Press Releases

  • Home
  • Investor Relations
  • Press Releases

IR Menu

IR Home
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Information Request
FAQs

Tertiary Nav - Press Releases

  • Press Releases
  • Media Statements

Press Releases

Date Title
5/11/07 AVI BioPharma Incorporated First Quarter 2007 Financial Results Conference Call Transcript
5/9/07 AVI BioPharma Announces First Quarter Financial Results
5/7/07 AVI BioPharma Receives DoD Contracts for Bioterrorism Response Therapies
5/2/07 AVI BioPharma and Ercole Biotech Announce License and Drug Development Agreement for Duchenne Muscular Dystrophy and Beta Thalassemia
5/2/07 AVI BioPharma Announces 2007 First Quarter Financial Results Conference Call
5/1/07 AVI BioPharma Reports Positive Pre-Clinical Influenza Data
4/20/07 AVI BioPharma Completes Purchase of Building for GMP Manufacturing
3/28/07 AVI BioPharma Chairman and CEO Resigns
3/23/07 AVI BioPharma Incorporated Fourth Quarter 2006 Financial Results Conference Call Transcript
3/15/07 AVI BioPharma Announces 2006 Fourth Quarter and Full Year Financial Results

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 70
  • Page 71
  • Page 72
  • Page 73
  • Current page 74
  • Page 75
  • Page 76
  • Page 77
  • Page 78
  • …
  • Next page next ›
  • Last page last »
Displaying 731 - 740 of 788

Toolkit

Print Page | Email Alerts | RSS Feeds | Contacts

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2023 Sarepta Therapeutics, Inc. All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • EU-U.S. and Swiss-U.S. Privacy Shield Policy